Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Rejection
This article was originally published in The Rose Sheet
Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.
You may also be interested in...
The National Advertising Division changes its review process to allow opposing firms some control over scheduling in the process and in resolving their disputes. The changes, recommended by ABA committees, also impose fees for both firms in appeals and allow more time for compliance with decisions.
NAD rejects TyraTech’s argument that because its Vamousse homeopathic works on lice and not people, non-human studies are adequate substantiation. Vamousse advertising referred to challenger Sanofi Pasteur’s Sklice prescription lice spray as less effective and more risky to human health.
NPA asks Congress to include supplements in legislation defining "medical expenses” covered by pre-tax health savings accounts. The trade group says industry would prefer supplements were included with OTC drugs in provision in recently passed COVID-19 relief legislation that changed pre-tax account rules.